Vaccines against coronavirus produced by the Anglo-Swedish company AstraZeneca and the Pfizer-BioNTech alliance are effective against Delta and Kappa variants of the COVID-19. Reuters reports citing a study by Oxford University.
"We are encouraged to see the non-clinical results published from Oxford and these data, alongside the recent early real-world analysis from Public Health England, provide us with a positive indication that our vaccine can have a significant impact against the Delta variant," AstraZeneca executive Mene Pangalos said.
It is known that last week, an analysis by the Public Health England showed that vaccines made by Pfizer and AstraZeneca offer high protection of more than 90% against hospitalization from the Delta variant.
As a reminder, a variant of the coronavirus, named Delta, was discovered in India in October last year. Since then, it has spread around the world, it is also found in Ukraine. Among the new symptoms are a runny nose, headache, and sore throat.
Maria Van Kerkhove, a WHO expert on responding to Covid-19, announced that not all vaccines work equally well with the Delta coronavirus strain.
It is known that this strain is 1.6 times more contagious than the Alfa strain (firstly discovered in the UK); 2.26 times more often it leads to hospitalization and 1.45 times more often to the resuscitation department. Meanwhile, the effect from the vaccines is mostly kept.